Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5191858 | PMC |
| http://dx.doi.org/10.18632/aging.101135 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Implications of An Evolving Regulatory Landscape on the Development of AI and ML in Medicine.
Pac Symp Biocomput
December 2024
Penn State Law, University Park, PA 16802, USA.
The rapid advancement of artificial intelligence and machine learning (AI/ML) technologies in healthcare presents significant opportunities for enhancing patient care through innovative diagnostic tools, monitoring systems, and personalized treatment plans. However, these innovative advancements might result in regulatory challenges given recent Supreme Court decisions that impact the authority of regulatory agencies like the Food and Drug Administration (FDA). This paper explores the implications of regulatory uncertainty for the healthcare industry related to balancing innovation in biotechnology and biocomputing with ensuring regulatory uniformity and patient safety.
View Article and Find Full Text PDFImmunome profiling in prostate cancer: a guide for clinicians.
Front Immunol
December 2024
Personalized Precision Medicine Chair, Universidad Autónoma de Madrid, Madrid, Spain.
Article Synopsis
- - Tumor immune microenvironment (TIME) significantly influences how prostate cancer (PC) responds to treatments and understanding mechanisms of resistance is crucial.
- - Research indicates that certain genomic changes, like microsatellite instability (MSI) and CDK12 bi-allelic loss, may increase response rates to immune therapies, but patient responses vary widely.
- - The review explores how immune cell interactions within tumors affect PC progression, how standard therapies impact immune responses, and the challenges in analyzing the immune landscape related to tumors.
Discovery of the First BRD4 Second Bromodomain (BD2)-Selective Inhibitors.
J Med Chem
December 2024
China-New Zealand Joint Laboratory of Biomedicine and Health, State Key Laboratory of Respiratory Disease, Guangdong Provincial Key Laboratory of Biocomputing, Institute of Drug Discovery, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, No. 190 Kaiyuan Avenue, Guangzhou 510530, China.
Pan-BD2 inhibitors have been shown to retain an antileukemia effect and display less dose-limiting toxicities than pan-BET inhibitors. However, it is necessary to consider the potential off-target toxicity associated with the inhibition of four BET BD2 proteins. To date, no BRD4 BD2 domain selective inhibitor has been reported.
View Article and Find Full Text PDFDNA Nanolock-Based Logic Gate-Directed Reciprocal Feedback for Stepwise Cell Typing and Combination Treatment.
Anal Chem
December 2024
Key Laboratory of Optic-electric Sensing and Analytical Chemistry for Life Science, MOE; College of Chemistry and Molecular Engineering, Qingdao University of Science and Technology, Qingdao 266042, P. R. China.
Article Synopsis
- There's a critical need for monitoring multiple biomarkers in living cells for accurate disease diagnosis and early intervention.
- A modular DNA logic gate nanomachine is introduced, which uses G-quadruplex-locked gold nanocages to identify cells and deliver drugs through a series of simple logic operations.
- This system effectively processes input from disease biomarkers to produce fluorescence signals, enabling precise cell identification and controlled treatments, expanding the potential of biocomputing in medical applications.
Incidence of post-acute COVID-19 symptoms across healthcare settings in seven countries: an international retrospective cohort study using routinely-collected data.
EClinicalMedicine
November 2024
Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.
Background: The World Health Organisation (WHO) has identified a range of symptomatic manifestations to aid in the clinical diagnosis of post-COVID conditions, herein referred to as post-acute COVID-19 symptoms. We conducted an international network cohort study to estimate the burden of these symptoms in North American, European, and Asian populations.
Methods: A federated analysis was conducted including 10 databases from the United Kingdom, Netherlands, Norway, Estonia, Spain, France, South Korea, and the United States, between September 1st 2020 and latest data availability (which varied from December 31st 2021 to February 28th 2023), covering primary and secondary care, nationwide registries, and claims data, all mapped to the Observational Medical Outcomes Partnership Common Data Model (OMOP CDM).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!